Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by AIM ImmunoTech Inc.
< Previous
1
2
Next >
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
April 25, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
April 18, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
April 15, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
April 11, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
April 10, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
April 02, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
March 28, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
March 26, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
March 25, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
March 22, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
March 20, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
March 15, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Launch of CEO Corner Platform
March 07, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
February 29, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
February 14, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
February 08, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
January 24, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
January 22, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
January 10, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting
January 05, 2024
From
AIM ImmunoTech Inc.
Via
Business Wire
Tickers
AIM
Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid
December 29, 2023
From
AIM ImmunoTech Inc.
Via
Business Wire
Tickers
AIM
AIM ImmunoTech Provides Update Regarding Annual Meeting
November 28, 2023
From
AIM ImmunoTech Inc.
Via
Business Wire
Tickers
AIM
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
November 27, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
November 21, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
November 15, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer
November 14, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
November 09, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer
November 08, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
November 06, 2023
From
AIM ImmunoTech Inc.
Via
Business Wire
Tickers
AIM
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
October 30, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.